Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): An effective adjuvant treatment for operable breast cancer

Women's Health

Volumn 2, Issue 4, 2006, Pages 527-537

  Martin, Miguel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Adjuvant chemotherapy; Breast cancer; Docetaxel; Taxanes

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CAPECITABINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BLOOD TRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSGEUSIA; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; PERIPHERAL EDEMA; POSTOPERATIVE CARE; REVIEW; SECOND CANCER; SEPSIS; SKIN TOXICITY; STOMATITIS; VOMITING;

EID: 33745698672     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.4.527     Document Type: Review

References (38)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352, 930-942 (1998).
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials Lancet 365, 1687-1717 (2005).
3. Bonadonna G, Valagussa P, Moliterni A et al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N. Engl. J. Med. 332, 902-906 (1995).
4. Fisher B, Brown AM, Dimitrov NV et al.: Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 8, 1483-1496 (1990).
5. Martin M, Villar A, Solé-Calvo A et al.: Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1,21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF, day 1,21) adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group. Ann. Oncol. 14, 833-842 (2003).
6. Fumoleau P, Kerbrat P, Romestaing P et al.: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J. Clin. Oncol. 21, 298-305 (2003).
7. Gianni L, Munzone E, Capri G et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effect in a dose-finding and sequence-finding study. J. Clin. Oncol. 13, 2688-2699 (1995).
8. Gehl J, Boesgaani M, Paaske T et al.: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann. Oncol. 19967, 687-693 (1996).
9. Mamounas EP, Bryant J, Lembersky BC et al.: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP-B 28. J. Clin. Oncol. 23, 3686-3696 (2005).
10. Henderson IC, Berry DA, Demetri GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976-983 (2003).
11. Misset JL, Dieras V, Gruia G et al.: Dose-finding study of docetaxel and doxorubicin in first-line teatment of patients with metastatic breast cancer. Ann. Oncol. 10, 553-560 (1999).
12. Nabholtz JM, Mackey JR, Smylie M et al.: Phase II study of docetaxel, doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J. Clin. Oncol. 19, 314-321 (2001).
13. Smith RE, Anderson SJ, Brown A et al.: Phase II trial of doxorubicin/ docetaxel/cyclophophosfamide for locally advanced and metastatic breast cancer: Results from NSABP trial BP-58. Clin. Breast Cancer 3, 333-340 (2002).
14. Mackey JR, Paterson A, Dirix LY et al.: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Assoc. Clin. Oncol. 21, 35a (2002) (Abstract 137).
15. O'Regan RM, Von Roenn JH, Carlson RW et al.: Final results of a phase II trial of preoperative TAC docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. Clin. Breast Cancer 6, 163-168 (2005).
16. Von Minckwitz G, Blohmer JU, Raab G et al.: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early stage breast cancer: The GEPARTRIO pilot study. Ann. Oncol. 16, 56-63 (2005).
17. Martin M, Pienkowski T, Mackey J et al.: Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302-2313 (2005).
18. Au HJ, Golmohammadi K, Verma S et al.: Cost-effectiveness of adjuvant chemotherapy for node + breast cancer: Modeling the downstream effects of adjuvant TAC versus FAC: Docetaxel. (T), adryamicin (A), cyclophosphamide (C) compared to 5-fluorouracil-AC. Breast Cancer Res. Treat. 94(Suppl. 1), S218 (2005) (Abstract 5038).
19. Martin M, Liuch A, Seguí MA et al.: Toxicity and health-related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors to TAC. GEICAM study 9805. froc. Am. Soc. Clin. Oncol. 29 (2005) (Abstract 604).
20. Martin M, Iluch A, Segui MA et al.: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin, cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann. Oncol. (2006) (Epub ahead of print).
21. Mamounas EP: NSABP breast canceR clinical trials: recent results and future directions. Clin. Med. Res. 1, 309-326 (2003).
22. Eiermann W, Pienkowski T, Crown J et al.: Phase III randomized trial comparing docetaxel in combination with dpxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in HER2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res. Treat. 94(Suppl. 1), S62-S63 (2005) (Abstract 1069).
23. Brain EGC, Bachelot T, Serin D et al.: Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 293, 2367-2371 (2005).
24. Vogel C, Mackey J, Martin M et al.: The role of growth factor support following neutropenic events in early-stage breast cancer patients treated with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC): a sub-analysis of BCIRG 001. Proc. Am. Soc. Clin. Oncol. 23, 46 (2004) (Abstract 677).
25. Nabholtz JM, Cantin J, Chang J et al.: Phase III trial comparing granocyte colony-estimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients with docetaxel/ doxorubicin/cyclophosphamide: Results of the BCIRG 004 trial. Clin. Breast Cancer 1, 268-275 (2002).
26. von Minckwitz G, Blohmer J, Loehr A et al.: Pegfilgastrim alone or with ciproflaxin significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC). Eur. J. Cancer 4(Suppl. 2), 151-152 (2006).
27. 90C followed by 8 weekly paclitaxel administrations: Interim efficacy analysis of GEICAM 9906 trial. Breast Cancer Res. Treat. 94 (Suppl. 1), S20 (2005) (Abstract 39).
28. Goldstein LJ, O'Neill A, Sparano, JA et al.: E2197: Phase III of AT vs AC in the adjuvant treatment of node-positive and high-risk node-negative breast cancer. J. Clin. Oncol. 23(Suppl. 16S), S6 (2005).
29. Roche H, Fumoleau P, Spielmann, M et al.: Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res. Treat. 88 (Suppl. 1) (2004) (Abstract 27).
30. Jones SE, Savin MA, Holmes FA et al.: Final analysis: TC (docetaxel/ cyclophosphamide), 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Breast Cancer Res. Treat. 94(Suppl. 1), S20 (2005) (Abstract 40).
31. Citron ML, Berry DA, Cirrincione C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003).
32. Hudis C, Citron M, Berry D et al.: Five-year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res. Treat. 94(Suppl. 1), S20 (2005) (Abstract 41).
33. Sparano, JA, Wang M, Martino S et al.: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer. Results of North American Breast Cancer Intergroup Tri al E1199. San Antonio Breast Cancer Symposium. (2005).
34. Romond EH, Perez EP, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
35. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
36. Slamon D, Eiermann W, Robert N et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study Breast Cancer Res. Treat. 94 (Suppl. 1), S4 (2005) (Abstract 1).
37. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
38. Berry DA, Cirrincione C, Henderson IC et al.: Effects of improvements in chemotherapy on disease-free and overall survival of estrogen receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res. Treat. 88 (Suppl. 1), S17 (2004) (Abstract 29).